Mark Jones

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised AviadoBio, a company focused on gene therapy for neurodegenerative disorders, on its exclusive option and license agreement with Astellas Pharma for AVB-101, an investigational, adeno-associated virus (AAV)-based gene therapy in Phase 1/2 development for patients with frontotemporal dementia with progranulin mutations (FTD-GRN).

Cooley advised Snyk, a leader in developer security, on its acquisition of Fugue, a cloud security and compliance company. Partners Ian Nussbaum and Ben Shribman led the Cooley team advising Snyk.

Cooley advised Snyk, a cybersecurity software startup, on its $530 million Series F financing, which brings the company’s valuation to $8.5 billion. Lawyers Ryan Naftulin, Kerry Corrigan and Mark Jones led the Cooley team advising Snyk.

Advising Snyk, the leader in cloud native application security, on its Series E financing, totalling $300 million. The round was co-led by Accel and Tiger Global, with participation from existing investors Addition, Boldstart Ventures, Canaan Partners, Coatue, GV (formally Google Ventures), Salesforce Ventures, Stripes and funds managed by BlackRock; new investors include Alkeon, Atlassian Ventures, Franklin Templeton, Geodesic Capital, Sands Capital Ventures and Temasek.